Akari Therapeutics CEO Abizer Gaslightwala Receives Stock Options Following Qualified Financing

This Form 4 filing discloses that Abizer Gaslightwala, CEO and Director of Akari Therapeutics Plc (AKTX), received stock option grants on June 24, 2026. The first grant of 5,500 American Depositary Shares (ADS) was part of a previously awarded option that vested due to the company closing a $5.5 million qualified financing. This option has an exercise price of $4.64 per share and expires on April 1, 2036. The second grant of 15,563 ADS was awarded with an exercise price of $14.63 per share, expiring on June 24, 2036. Both options were granted at $0 cost to the executive and represent rights to purchase ordinary shares of the company. The filing indicates these are derivative securities transactions reported under Section 16 of the Securities Exchange Act.